Pacira BioSciences(PCRX) Stock Price Today

US Stock MarketDetailed Quotes

PCRX Pacira BioSciences

Watchlist

27.000
-0.140-0.52%

Close Apr 29 16:00 ET

27.000
0.0000.00%

Post 16:05 ET

1.25BMarket Cap-12.56P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025
GlobeNewswireApr 29 08:00 ET
Pacira BioSciences Announces 2-Yr Data On PCRX-201 Gene Therapy Demonstrating Sustained Knee Pain Relief
BenzingaApr 28 08:05 ET
Express News | Pacira BioSciences To Present 104-Week Data Of PCRX-201 For Patients With Mild To Severe Osteoarthritis Of Knee
BenzingaApr 22 16:02 ET
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
BenzingaApr 21 10:36 ET
Express News | Doma Perpetual - Believes Pacira's Stock Is Undervalued
ReutersApr 21 08:15 ET
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
PR NewswireApr 21 08:15 ET

Comments

Teddy123

Apr 23 12:27

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

$Pacira BioSciences (PCRX.US)$
Revolutionary Gene Therapy Shows 2-Year Effectiveness for Knee Arthritis After Single Dose

Teddy123

Apr 21 20:17

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

$Pacira BioSciences (PCRX.US)$
Pacira's Largest-Ever $300M Buyback Signals Major Growth Phase - Key Investor Catalyst Revealed

Teddy123

Apr 3 20:31

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

$Pacira BioSciences (PCRX.US)$
Game-Changing Knee Osteoarthritis Gene Therapy Advances After 2-Year Pain Relief Success

Value investorr

Aug 24, 2024 00:25

My last point: looking into the future of PCRX.

$Pacira BioSciences (PCRX.US)$ $iShares Russell 2000 ETF (IWM.US)$
Besides all the information that is publicly available and that I’ve posted in my previous two comments. Here’s something to keep in mind for PCRX future if you want to make your decision to buy, hold, or sell:
1. Diversification of product pipeline greatly reduces the risk of further top-line (revenue) erosion even if we assume the worst case scenario for Experal (which itself is ex...

Value investorr

Aug 19, 2024 23:03

A undervalued keeper

$Pacira BioSciences (PCRX.US)$ I believe whoever saw my last comment om this stock has generated a good return over the past week. I think the opportunity is still not fully capitalized and fundamental reasonings from last time still persist.
Additionally, just look at the imsider activities. Wow, from CEO to multiple directors, they are buying and loading a ton of shares and no one is selling. This is just another signal supports my theory and the share price. From its funda...

Share Your Profit/Loss

PCRX Pacira BioSciences

Trade Overview

Capital Trend

News

Comments

Market Insights

Latest News

Investment Course

Discussing

Earnings Season Underway